Syndax Pharmaceuticals, Inc. — Net Income by Fiscal Year
12 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/69df7ecb-b3d3-47a4-aecc-b8da79eaaae7/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-285.4M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-197859 |
| FY 2024 | $-318.8M | 2024-01-01 – 2024-12-31 | evidence 0001193125-26-197859 |
| FY 2023 | $-209.4M | 2023-01-01 – 2023-12-31 | evidence 0001193125-26-197859 |
| FY 2022 | $-149.3M | 2022-01-01 – 2022-12-31 | evidence 0001193125-26-197859 |
| FY 2021 | $24.9M | 2021-01-01 – 2021-12-31 | evidence 0001193125-26-197859 |
| FY 2020 | $-73.2M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-012607 |
| FY 2019 | $-56.0M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-009016 |
| FY 2018 | $-74.0M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-006772 |
| FY 2017 | $-60.8M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-004911 |
| FY 2016 | $-44.5M | 2016-01-01 – 2016-12-31 | evidence 0001193125-17-081863 |
| FY 2015 | $-24.1M | 2015-01-01 – 2015-12-31 | evidence 0001193125-17-081863 |
| FY 2014 | $-19.8M | 2014-01-01 – 2014-12-31 | evidence 0001193125-17-081863 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Syndax Pharmaceuticals, Inc. — all facts · Revenue · Operating Income